JP2010510323A5 - - Google Patents

Download PDF

Info

Publication number
JP2010510323A5
JP2010510323A5 JP2009538506A JP2009538506A JP2010510323A5 JP 2010510323 A5 JP2010510323 A5 JP 2010510323A5 JP 2009538506 A JP2009538506 A JP 2009538506A JP 2009538506 A JP2009538506 A JP 2009538506A JP 2010510323 A5 JP2010510323 A5 JP 2010510323A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
composition according
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009538506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510323A (ja
JP5410293B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/085402 external-priority patent/WO2008064321A2/en
Publication of JP2010510323A publication Critical patent/JP2010510323A/ja
Publication of JP2010510323A5 publication Critical patent/JP2010510323A5/ja
Application granted granted Critical
Publication of JP5410293B2 publication Critical patent/JP5410293B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009538506A 2006-11-21 2007-11-21 Ｇｍ−ｃｓｆアンタゴニストを用いて慢性炎症性疾患を治療する方法 Expired - Fee Related JP5410293B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86078006P 2006-11-21 2006-11-21
US60/860,780 2006-11-21
US90274207P 2007-02-21 2007-02-21
US60/902,742 2007-02-21
PCT/US2007/085402 WO2008064321A2 (en) 2006-11-21 2007-11-21 Methods of treating chronic inflammatory diseases using a gm-csf antagonist

Publications (3)

Publication Number Publication Date
JP2010510323A JP2010510323A (ja) 2010-04-02
JP2010510323A5 true JP2010510323A5 (enExample) 2011-01-13
JP5410293B2 JP5410293B2 (ja) 2014-02-05

Family

ID=39386167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009538506A Expired - Fee Related JP5410293B2 (ja) 2006-11-21 2007-11-21 Ｇｍ−ｃｓｆアンタゴニストを用いて慢性炎症性疾患を治療する方法

Country Status (15)

Country Link
US (2) US20080206241A1 (enExample)
EP (2) EP2101780B1 (enExample)
JP (1) JP5410293B2 (enExample)
KR (1) KR101517251B1 (enExample)
CN (2) CN105435223A (enExample)
AU (1) AU2007323541B2 (enExample)
BR (1) BRPI0719109A2 (enExample)
CA (1) CA2670288C (enExample)
EA (1) EA200900709A1 (enExample)
ES (1) ES2432173T3 (enExample)
IL (1) IL198829A0 (enExample)
MX (1) MX2009005398A (enExample)
NZ (1) NZ598345A (enExample)
SG (1) SG176503A1 (enExample)
WO (1) WO2008064321A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
CA2711763A1 (en) * 2008-01-15 2009-07-23 Kalobios Pharmaceuticals, Inc. Methods of treating bone-loss disorders using a gm-csf antagonist
WO2009126659A1 (en) * 2008-04-07 2009-10-15 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
KR101824512B1 (ko) * 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
DK2376121T4 (da) * 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
WO2010093814A1 (en) * 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
CA2759506A1 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
US20120116059A1 (en) * 2009-05-05 2012-05-10 Morphosys Ag Treatment For M Treatment For Multiple Sclerosis
BR112013033944A2 (pt) * 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) * 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
JP6360696B2 (ja) * 2014-03-18 2018-07-18 日本光電工業株式会社 血液検査装置および血液検査方法
AU2015263285A1 (en) * 2014-05-19 2016-11-24 Medimmune Limited Treatment for rheumatoid arthritis
US20180236098A1 (en) * 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
DK3328887T3 (da) 2016-09-19 2021-09-20 I Mab Biopharma Hangzhou Co Ltd Anti-GM-CSF antistoffer og anvendelser deraf
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
CN111757744A (zh) * 2017-10-02 2020-10-09 人源股份有限公司 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US12624086B2 (en) * 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
JP2023551549A (ja) * 2020-12-04 2023-12-08 シーエスエル イノベーション プロプライアタリー リミティド 炎症性皮膚状態を治療する方法
US20240317846A1 (en) * 2021-03-08 2024-09-26 Humanigen, Inc. Methods for treating coronavirus infection and resulting inflammation-induced lung injury
CN116887856A (zh) * 2022-01-20 2023-10-13 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用
CN117547474A (zh) * 2022-08-03 2024-02-13 苏州隽德生物科技有限公司 含磺化杯芳烃的护肤品组合物、药用组合物、及磺化杯芳烃的用途
CN119769464B (zh) * 2025-01-14 2026-07-31 浙江中医药大学 Mtx诱导的骨髓抑制大鼠模型适宜给药剂量的确立方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
NZ234479A (en) * 1989-07-14 1992-03-26 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
GB0224082D0 (en) * 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
CN102225194B (zh) * 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
NZ545447A (en) * 2003-07-23 2010-03-26 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
US7981843B2 (en) 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
ES2918209T3 (es) 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
US20080305079A1 (en) * 2006-01-06 2008-12-11 Mount Sinai School Of Medicine Of New York University Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
KR101395515B1 (ko) * 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
KR101481844B1 (ko) * 2006-03-27 2015-01-13 메디뮨 리미티드 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
DE102006033837A1 (de) * 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist

Similar Documents

Publication Publication Date Title
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
US12006359B2 (en) Methods for altering body composition by administering anti-pro/latent myostatin antibodies
JP5537740B2 (ja) Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
US20140212423A1 (en) Blood-brain barrier penetrating dual specific binding proteins
US20160002343A1 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
CN104903352A (zh) 多价结合蛋白组合物
JP2019514844A5 (enExample)
JP2017512765A5 (enExample)
JP2017535257A5 (enExample)
JP2020513791A5 (enExample)
JP2017501711A5 (enExample)
RU2016129247A (ru) Антитела с двойной специфичностью
JP2014533659A5 (enExample)
JP2004536072A5 (enExample)
HRP20220405T1 (hr) Protutijela protiv ngf i njihova upotreba
JP2020536532A5 (enExample)
WO2009140348A4 (en) Anti-il-6/il-6r antibodies and methods of use thereof
JP2011520898A5 (enExample)
JP2017537105A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP2010520290A5 (enExample)
US20230235069A1 (en) Treatment of atopic dermatitis
JP2017507131A5 (enExample)
JP2016094424A5 (enExample)
JP2015509960A5 (enExample)
JP2013508292A5 (enExample)